Syndax Pharmaceuticals, Inc. (NasdaqGS: SNDX)
Health Care · Biotechnology · US
$19.65
-0.96% today · +25.5% 1Y
Syndax Pharmaceuticals, Inc. (NasdaqGS: SNDX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.75B and employs 298 people.
Over the last twelve months the share price has gained 25.5%, trading between 12.99 and 25.59.
Tweenvest scores Syndax Pharmaceuticals, Inc. across four factors: quality 32/100, value 75/100. Its strongest factor is value.
SNDX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.75B
- Revenue (TTM)
- $252.25M
- P/E
- —
- EPS
- -2.51
- Dividend yield
- —
- Beta (5Y)
- 0.37
- 52-week high
- $25.59
- 52-week low
- $12.99
- Avg volume (3M)
- —
- Shares outstanding
- 89.30M
- Employees
- 298
- Next earnings
- —
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
- ISIN
- US87164F1057
- Founded
- 2005
- Listed since
- Mar 2, 2016
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.